Cumberland Pharmaceuticals Inc. has entered into an agreement with a Chinese pharmaceuticals firm that will introduce two of the Nashville-based company’s brands to the world’s second-largest market for prescription medicine. The exclusive deal gives Winhealth Pharma Group the licensing rights to sell Cumberland’s drug brands Acetadote and Caldolor in China. CEO A.J. Kazimi said the agreement is expected to generate $290 million in revenue for Cumberland during its first 10 years. The deal is the result of a company-initiated strategic review of Cumberland’s brands and partnerships, which was announced in March.